Pharmacotherapy of Alcoholism

Charles P. O’Brien*, Margaret R. Rukstalis, and Michael F. Stromberg

University of Pennsylvania
Treatment Research Center
3900 Chestnut Street
Philadelphia, Pennsylvania 19104
tel: (215) 222-3200 ext. 132
fax: (215) 386-6770
e-mail: obrien@research.trc.upenn.edu

1.           Acquas E, Meloni M, DiChiara G. Blockage of d-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur J Pharmacol  1993;230:239-241.

2.           Addolorato G, Castelli E, Stefanini G, Casella G, Caputo F, Marsigli L, Bernardi M, Gasbarrini G, Group GS.  An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol & Alcoholism  1996;31:341-345.

3.           Addolorato G, Caputo F, Stefanini G, Gasbarrini G. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addiction  1997;92:1035-1036.

4.           Azrin N, Sisson R, Meyers R, Godley M.  Alcoholism treatment by disulfiram and community reinforcement therapy.  J Beh Ther Exp Psych  1982;13:105-112.

5.           Babor T, Hoffman M, DelBoca F, Hesselbrock V, Meyer R, Dolinsky Z, Rounsaville B. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity.  Arch Gen Psychiatry  1992;49:599-608.

6.           Benjamin D, Grant E, Pohrecky L.  Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats.  Brain Research  1993;621:137-140.

7.           Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.  Alcoholism: Clinical and Experimental Research  1998;22:573-579.

8.           Biggio G, Cibin M, Diana M, Fadda F, Ferrara S, Gallimberti L, Gessa G, Mereu G, Rossetti Z, Serra M.  Suppression of voluntary alcohol intake in rats and alcoholics by gamma hydroxybutyric acid: a non-GABAergic mechanism.  Advances in Biochemical Psychopharmacology  1992;47:281-288.

9.           Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre J, Chretien P, Durlach J.  A  homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?  Pharmacology Biochemistry and Behavior  1984;21:787-789.

10.       Borg S, Kvande H, Sedvall G.  Central norepinephrine metabolism during alcohol intoxication in addicts and healthy volunteers. Science  1981;213:1135-1137.

11.       Borg V.  Bromocriptine in the prevention of alcohol abuse.   Acta Psychiatr Scand   1983;68:110-110.

12.       Brodie M, Shefner S, Dunwiddie T.  Ethanol increases the firing rate of dopamine neurons in the rat.   Brain Research  1990;580:65-69.

13.       Brodie M, Trifunovic R, Shefne S.  Serotonin potentiates ethanol-induced excitation of ventral tegmental area neurons in brain slices from three different rat strains.  J Pharmacol and Experi Therapeu  1995;273:1139-1146.

14.       Bruno F.  Buspirone and the treatment of alcohol abuse. Psychopathology  1989;22(1):49-59.

15.       Buydens-Branchey L, Branchey MH, Noumair D.  Age of alcoholism onset. I. Relationship to psychopathology.  Archives of General Psychiatry  1989a;46:225-230.

16.       Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS.  Age of alcoholism onset. II. Relationship to susceptibility to serotonin precursor availability. Archives of General Psychiatry  1989b;46:231-236.

17.       Cadoret R, Cain C, Grove W.  Development of alcoholism in adoptees raised apart from alcoholic biologic relatives.  Arch Gen Psychiatry  1980;37:561-563.

18.       Campbell A, McBride W.  Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens.  Pharmacology, Biochemistry and Behavior  1995;51:835-842.

19.       Carboni E, Elio A, Frau R, DiChiara G. Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release.  European J Pharmacology  1989;164:515-519.

20.       Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D.  Disulfiram treatment of alcoholism. Br J Psychiatry  1992;161:84-89.

21.       Chou SP, Dawson DA.  A study of the gender differences in morbidity among individuals diagnosed with alcohol abuse and/or dependence. Journal of Substance Abuse  1994;6:381-392.

22.       Ciraulo D, Alderson L, Chapron D, Jaffe J, Subbarao B, Kramer P.  Imipramine disposition in alcoholics.   J Clin Psychopharmacol  1982;2:2-7.

23.       Ciraulo DA, Barnhill JG, Jaffe JH.  Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.  Clin Pharmacology Therapeutics 1988;43:509-518.

24.       Cloninger C, Bohman M, Sigvardsson S.  Inheritance of alcohol abuse: cross-fostering analysis of adopted men.  Arch Gen Psychiatry  1981;38:861-868.

25.       Cloninger C, Bohman M, Sigvardsson S, von Knorring A.  Psychopathology in adopted-out children of alcoholics: the Stockholm adoption study.  In: Galanter M,  ed. Recent Developments in Alcoholism.  New York: Plenum Press, 1985;37-51.

26.       Cloninger C.  Neurogenetic adaptive mechanisms in alcoholism. Science  1987;236:410-416.

27.       Cornelius J, Salloum I, Cornelius M, Perel J, Thase M, Ehler J, Mann J.  Fluoxetine trial in suicidal depressed alcoholics.  Psychopharmacol Bull  1993;29:195-199.

28.       Cornelius JR, Salloum IM, Cornelius MD, Ehler JG, Perel JM.  Fluoxetine in depressed alcoholics.  A double blind, placebo-controlled trial.  Arch Gen Psychiatry  1997;54(8):700-705.

29.       Cotton N.  The familial incidence of alcoholism: a review.  J Stud Alcohol  1979;40:89-116.

30.       Criado J, Lee R-S, Berg G, Henriksen S.  Sensitivity of the nucleus accumbens neurons in vivo to intoxicating doses of ethanol.  Alcoholism: Clinical and Experimental Research  1995;19:164-169.

31.       Critcher E, Lin C, Patel J, Myers R.  Attenutation of alcohol drinking in tetrahydroisoquinoline-treated rats by morphine and naloxone.  Pharmacology, Biochemistry and Behavior  1983;18:225-229.

32.       Cunningham C, Malott D, Dickinson S, Risinger F.  Haloperidol does not alter expression of ethanol-induced conditioned place preference.  Behav Brain Res  1992;50:1-5.

33.       Davidson KM, Ritson EB.  The relationship between alcohol dependence and depression.  Alcohol and Alcoholism  1993;28:147-155.

34.       De Waele J-P, Kiianmaa K, Gianoulakis C.  Distribution of the m and d opioid binding sites in the brain of the alcohol preferring AA and alcohol avoiding ANA lines of rats.  J Pharmacol and Experi Therapeu  1995;275:518-527.

35.       De Waele J-P, Gianoulakis C.  Characterization of m and d opioid receptors in the brain of the C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption.  Alcoholism: Clin and Experi Res  1997;21:754-762.

36.       DiChiara G, Imperato A.  Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats.  Eur J Pharmacol  1985;115:131-132.

37.       Dongier M, Vachon L, Schwartz  G.  Bromocriptine in the treatment of alcohol dependence.  Alcoholism: Clinical and Experimental Research  1991;15:970-977.

38.       Dorus W, Ostrow D, Anton R, Cushman P, Collins J, Schaefer M, Charles H, Desai P, Hayashida M, Malkerneker U, Willenbring O, Fiscella R, Sather M.  Lithium treatment of depressed and nondepressed alcoholics.  JAMA  1989;262:1646-1652.

39.       Fadda F, Garau B, Marchei F, Colombo G, Gessa G.  MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary enthanol consumption in alcohol-preferring rats.   Alcohol and Alcoholism  1991;26(2):107-110.

40.       Fawcett J, Clark D, Gibbons R, Aagesen C, Pisani V, Tilkin J, Sellers D, Stulzman D.  Evaluation of lithium therapy for alcoholism.  J Clin Psychiatry  1984;45:494-499.

41.       Fluoxetine bulimia nervosa collaboration study group.  Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double blind trial.  Arch Gen Psychiatry  1992;49:139-147.

42.       Froehlich J, Harts J, Lumeng L, Li T-K.  Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference.  Pharmacol Biochem Behav 1990;35:385-390.

43.       Froehlich J, Swiftly M, Harts J, Lumeng L, Li  T-K.  Importance of delta  opioid receptors in maintaining high alcohol drinking.  Psychopharmacology  1991;103:467-472.

44.       Fuller R, Roth H.  Disulfiram for the treatment of alcoholism: an evaluation in 128 Men.  Ann Intern Med  1979;90:901-904.

45.       Fuller R, Branchey L, Brightwell D, Derman R, Emrick C, Iber F, James K,  Lacoursiere R, Lee K, Lowenstam I, Manny I, Neiderhiser D, Nocks S, Shaw J. Disulfiram treatment of alcoholism: a Veterans Administratin cooperative study. JAMA  1986;256:1449-1455.

46.       Galloway G, Frederick S, Staggers F, Gonzales M, Stalcup S, Smith D.  Gamma hydroxybutyrate:an emerging drug of abuse that causes physical dependence. Addiction  1997;92:89-96.

47.       George D, Lindquist T, Rawlings R, Eckardt M, Moss H, Mathis C, Martin P, Linnoila M.  Pharmacologic maintenance of abstinence in patients with alcoholism:  no efficacy of 5-hydroxytryptophan or levodopa.  Clinical Pharmacology and Therapeutics  1992;52(2):553-560.

48.       Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M.  Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Current Therapeutic Research  1992;52:291-295.

49.       Gessa G, Muntoni F, Collu M, Vargiu L, Mereu G.  Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area.  Brain Research  1985;348(1):201-203.

50.       Gianoulakis C, Beliveau D, Angelogianni P, Meaney M, Thavundayil J, Tawar V, Dumas M.  Different pituitary B-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism.  Life Sciences  1989;45:1097-1109.

51.       Gianoulakis C, Krishnan B, Thavundayil J.  Enhanced sensitivity of pituitary b-endorphin to ethanol in subjects at high risk of alcoholism.  Arch Gen Psychiatry  1996;53:250-257.

52.       Gilbert P, Martin W. The effects of morphine- and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.  J Pharmacol and Experi Therapeu  1976;198:66-82.

53.       Gill K, Amit Z, Koe B.  Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats.  Alcohol  1988;5:349-354.

54.       Goldman D.  Molecular markers for linkage of genetic loci contributing to alcoholism. In: Galanter M, ed. Recent Developments in Alcoholism. New York: Plenum Press, 1988;333-349.

55.       Gongwer M, Murphy J, McBride W, Lumeng L, Li T-K.  Regional brain contents of  serotonin, dopamine and their metabolites in the selectively bred high- and low-alcohol drinking lines of rats.   Alcohol  1989;6:317-320.

56.       Gonzales R, Weiss F. Supression of ethanol-reinforcing behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in nucleus accumbens.  Neuroscience  1998;18(24):10663-10671.

57.       Goodwin D, Schulsinger F, Hermansen L, Guze S, Winokur G.  Alcohol problems in adoptees raised apart from alcoholic biological parents.   Arch Gen Psychiatry  1973;28:238-243.

58.       Gorelick D.  Serotonin uptake blockers and the treatment of alcoholism.  In: Galanter M, ed. Recent Developments in Alcoholism.  New York: Plenum Press, 1989; 267-278.

59.       Haraguchi M, Samson H, Toliver G. Reduction in oral ethanol self-administration in the rat by the 5-HT uptake, flouxetine.  Pharmacology, Biochemistry and Behavior  1990;35(1):259-262.

60.       Harris R, Brodie M, Dunwiddie T.  Possible substrates of ethanol reinforcement: GABA and dopmaine.   Annals of the New York Academy of Science  1992;654:61-69.

61.       Heath A, Meyer J, Jardine R, Martin N.  The inhteritance of alcohol consumption patterns in a general population twin sample: I Multidimensional scaling of quantity/frequency data.   J Stud Alcohol  1991a;52:345-352.

62.       Heath A, Meyer J, Jardine R, Martin N.  The inheritance of alcohol consumption patterns in a general population twin sample: II Determinants of consumption frequency and quantity consumed. J Stud Alcohol  1991b;52:425-433.

63.       Herz A.  Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997;129:99-111.

64.       Hesselbrock MN. Gender comparison of antisocial personality disorder and depression in alcoholism.  Journal of Substance Abuse  1991;3:205-219.

65.       Heyser C, Schulteis G, Durbin P, Koob G.  Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.  Neuropsychopharmacology  1998;18:125-133.

66.       Hodge C, Samson H, Lewi R,  Erikson H.  Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS205-930.  Alcohol  1993;10:191-196.

67.       Hodge C, Samson H, Chappelle A.  Alcohol self-administration: further examination of the role of dopamine receptors in the nucleus accumbens.  Alcoholism: Clinical and Experimental Research  1997;21:1083-1091.

68.       Hoffman P, Rabe C, Moses F, Tabakoff B.  NMDA receptors and ethanol: inhibition of calcium flux and cyclic GMP production.  Journal of Neurochemistry  1989;52:1937-1940.

69.       Holter S, Landgraf R, Zieglgansberger W, Spanagel R.  Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation.  Alcoholism: Clinical and Experimental Research  1997;21:862-868.

70.       Honkanen A, Vilamo L, Wegelius K, Sarviharju M, Hyytia P, Korpi E.  Alcohol drinking is reduced a m1- but not a d-opioid receptor antagonist in alcohol-preferring rats.  European Journal of Pharmacology  1996;304:7-13.

71.       Hubbell C, Czirr S, Hunter G, Beaman C, LeCann N, Reid L.  Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations.  Alcohol  1986;3:39-54.

72.       Hughes J, Cook C.   The efficacy of disulfiram:  a review of outcome studies.  Addiction  1997;92:381-395.

73.       Hyytia P, Sinclair J.  Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats.  Alcohol Clin Exp Res  1993;17:631-636.

74.       Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther  1986;239:219-228.

75.       Jaffe J, Kranzler H, Ciraulo D.  Drugs used in the treatment of alcoholism.  In: Mendelson J, Mello M, eds. Medical Diagnosis and Treatment of Alcoholism.   New York: McGraw-Hill, 1992;421-461.

76.       Jensen S, Christoffersen C, Noerregaard A.  Apomorphine in outpatient treatment of alcohol intoxication and abstinence: a double-blind study.  Br J Addiction 1977;72:325-330.

77.       Johnson B, Jasinski D, Galloway G, Kranztler H, Weinreib R, Anton R, Mason B, Bohn M, Pettinati H, Rawson R, Clyde C, Group RS.  Ritanserin in the treatment of alcohol dependence - a multicenter clinical trial.  Psychopharmacology  1996;128:206-215.

78.       Jones BM, Jones MK.  Women and alcohol:  Intoxication, metabolism, and the menstrual cycle.  In: Greenblatt M, Schuckit MA, eds. Alcoholism Problems in Women and Children.  New York: Grune and Stratton,  1976;103-136.

79.       Kadden RM, Cooney NL, Getter H, Litt MD. Matching alcoholics to coping skills or interactional therapies: Posttreatment results. Journal of Consulting and Clinical Psychology  1989;57:698-704.

80.       Kendler K, Heath A, Neale M, Kessler R, Eaves L.  A poulation-based twin study of alcoholism in women. JAMA  1992;268:1877-1882.

81.       Kiianmaa K, Andersson K, Fuxe K. On the role of ascending dopamine systems in the control of voluntary ethanol intake and ethanol intoxication.  Pharmacol Biochem Behav  1979;10:603-608.

82.       Kiianmaa K, Nurmi M, Nykanen I, Sinclair J.  Effect of ethanol on extracellular dopamine in the nucleus accumbens of alcohol-preferring AA and alcohol-avoiding ANA rats.  Pharmacology, Biochemistry and Behavior  1995;52:29-34.

83.       King A, Volpicelli J, Frazer A, O'Brien C. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharm  1997;129:15-22.

84.       Knapp D, Pohrecky L.  Zaclopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats.  Pharmacology, Biochemistry and Behavior  1992;41:847-850.

85.       Koob G.  Neural mechanisms of drug reinforcement.  Annals of The New York Academy of Science  1992;654:171-191.

86.       Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ. Buspirone treatment of anxious alcoholics: A placebo-controlled trial.  Archives of General Psychiatry  1994a;51:720-731.

87.       Kranzler H, Anton R.  Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism.  J Consult and Clin Psychology  1994b;62(6):116-1126.

88.       Kranzler H, Burleson J, Korner P, Boca F, Bohn M, Brown J, Liebowitz M. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry  1995;152:391-397.

89.       Krishnan-Sarin S, Portoghese P, Li T-K, Froehlich J.  The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacology, Biochemistry and Behavior  1995a;52:153-159.

90.       Krishnan-Sarin S, Jing S, Kurtz D, Zweifel M, Portoghese P, Li T-K, Froehlich J.  The delta opioid receptor antagonist nalrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference.  Psychopharmacology  1995b;120:177-185.

91.       Krishnan-Sarin S, Wand G, Li XW, Portoghese P, Froehlich J.  Effect of m opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacology, Biochemistry and Behavior  1998;59:627-635.

92.       Kristenson H. How to get the best out of antabuse. Alcoholism  1995;30:775-783.

93.       Lankford M, Bjork A, Myers R.  Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats.  Alcohol  1996;13:399-404.

94.       Le A, Poulos C, Quan B, Chow S.  The effects of blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm. Brain Research  1993;630:330-332.

95.       LeMagnen J, Tran G, Durlach J, Martin C.  Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by ca-acetyl homotaurinate.  Alcohol   1987;4:97-102.

96.       Lewis M.  Alcohol reinforcement and neuropharmacological therapeutics. Alcoholism 1996;31(1):17-25.

97.       Lhuintre J, Daoust M, Moore N, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B.  Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.  Lancet  1985;1(8436):1014-1016.

98.       Lhuintre J, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F.   Acamprosate appears to decrease alcohol intake in weaned alcoholics.  Alcohol and Alcoholism  1990;25(6):613-622.

99.       Lieber C.  Medical disorders of alcoholism. The New England Journal of Medicine  1995;333:1058-1065.

100.   Litt M, Babor T, DelBoca F, Kadden R, Cooney N.  Types of alcoholics, II: application of an empirically derived typology to treatment matching. Arch Gen Psychiatry  1992;49:609-614.

101.   Littleton J.  Acamprosate in alcohol dependence: how does it work?  Addiction 1995;90:1179-1188.

102.   Lovinger D, White G, Weight F.  Ethanol inhibits NMDA-activated ion current in hippocampal neurons.  Science 1989;243:1721-1724.

103.   Malcolm R, Anton R, Randall C, Johnston A, Brady K, Thevos A.  A placebo-controlled trial of buspirone in anxious inpatient alcoholics.  Alcohol Clin Exp Res   1992;16:1007-1013.

104.   Malec E, Malec T, Gagne MA, Dongier M.  Buspirone in the treatment of alcohol dependence: A placebo-controlled trial.  Alcoholism: Clinical and Experimental Research  1996a;20:307-312.

105.   Malec TS, Malec EA, Dongier M.  Efficacy of buspirone in alcohol dependence: A review.  Alcoholism: Clinical and Experimental Research  1996b;20:853-858.

106.   Mason B, Ritvo E, Morgan R, Salvato F, Goldberg G, Welch B, Mantero-Atienza E.  A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence.  Alcohol Clin Exp Res  1994;18:1162-1167.

107.   Mason BJ.  Dosing Issues in the Pharmacotherapy of Alcoholism.  Alcoholism:Clinical and Experimental Research  1996;20:10A-16A.

108.   McBride W, Murphy J, Lumeng L, Li T-K. Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats.  Alcohol  1990;7:199-205.

109.   McLellan A, Alterman A, Cacciola J, Metzger D, O'Brien C.  A new measure of substance abuse treatment: initial studies of the treatment services review.  J Nervous and Mental Disease  1992;180:101-110.

110.   Mereu F, Fadda F, Gessa G.  Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats.  Brain Res  1984;292:63-69.

111.   Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA.  Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials.  New England Journal of Medicine  1993;329:292-296.

112.   Minabe,Y, Ashby CJ, Schwartz J, Wang R.  The 5-HT3 receptor antagonists LY277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells.  European Journal of Pharmacology  1991;209:1543-1550.

113.   Mocsary Z, Bradberry C.  Effect of ethanol on extracellular dopamine in nucleus accumbens: comparison between Lewis and Fischer F344 rat strains.  Brain Research  1996;706:194-198.

114.   Monti J, Alterwain P.  Ritanserin decreases alcohol intake in chronic alcoholics Lancet  1991337:60.

115.   Morrisett R, Swartzwelder H.  Attenuation of hippocampal long-term potentiation by ethanol: a patch-clamp of glutamatergic and GABAergic mechanisms.  J Neurosci  1993;13:2264-2272.

116.   Murphy J, McBride W, Lumen, L, Li T.-K.  Monoamine and metabolite levels in CNS regions of the P line of alcohol-preferring rats after acute or chronic ethanol treatment. Pharmacology, Biochemistry and Behavior  1983;19:849-856.

117.   Murphy J, Walte,M, Gatto G, McBride W, Lumeng L, Li T-K.  Monoamine uptake inhibitors attenuate ethanol intake in alcohol preferring P rats.  Alcohol  1985;2:349-352.

118.   Murphy J, Waller M, Gatto G, McBridge W, Lumeng L, Li T-K.  Effects of fluoxetine on the intragastic self-administration of ethanol in the alcohol preferring P line or rats.  Alcohol  1988;5:283-286.

119.   Myers R, Critcher E. Naloxone alters alcohol drinking induced in the rat by tetrahydopapaveroline (THP) infused ICV. Pharmacol, Biochem and Behav     1982;16:827-836.

120.   Myers R, Lankford M. Suppression of alcohol preference in high alcohol drinkings rates: efficacy of amperozide vs. naltrexone. Neuropsychopharmacology  1996;14:139-149.

121.   Nadal R, Prat G, Pallares M, Hernadez-Torres M, Ferr N.  Effects of bromocriptine on self-administration of sweetened ethanol solutions in rats. Psychopharmacology 1996;128:45-53.

122.   Naranjo C, Sellers E, Roach C, Woodley D, Sanchez-Craig M, Sykora K.  Zimelidine-induced variation in alcohol intake by nondepressed heavy drinkers. Pharmacol Ther  1984;35:374-381.

123.   Naranjo C, Sellers E, Sullivan J, Woodley D, Kadlec K, Sykora K.  The serotonin uptake inhibitor citalopram attenuates ethanol intake.  Clin Pharmacol Ther   1987;41:266-274.

124.   Naranjo C, Bremmer K.  Evaluation of the effects of serotonin uptake inhibitors in alcoholics: a review.  In: Naranjo C, Sellers E, eds.  Novel Pharmacological Interventions for Alcoholism. New York: Springer-Verlag, 1992;105-120.

125.   Naranjo C, Poulos C, Lanctot K, Bremner K, Kwok M, Umana M.  Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers:  desire to drink, alcohol intake and related effects.   Addiction  1995;90:893-905.

126.   Naranjo CA, Dongier M, Bremner E.  Long-acting injectable bromocriptine does not reduce relapse in alcoholics.  Addiction  1997;92:969-978.

127.   Nathan P.  Outcomes of treatment for alcoholism: current data.  Anna Behav Med 1986;8:40-46.

128.   National Institute of Alcohol and Alcohol Abuse.  Ecomonic costs of alcohol abuse. Seventh Special Report to the Congress on Alcohol and Health  1990:(Jan)174.

129.   O'Malley S, Jaffe A, Chang G, Schottenfeld R, Meyer R, Rounsaville B.  Naltrexone and coping skills therapy for alcohol dependence.  Arch Gen Psychiatry  1992;49:881-887.

130.   Peters D, Faulds D.  Tiapride: a review of its pharmacology and therapeutic in the management of alcohol dependence syndrome.  Drugs  1994;47:1010-1032.

131.   Pettinati HM.  Use of seratonin selective pharmacotherapy in the treatment of alcohol dependence.  Alcoholism: Clinical and Experimental Research  1996;20:23A-29A.

132.   Pettinati HM.  Does 5-HT pharmacotherapy have a role in alcohol treatment? Research Society on Alcoholism Annual Meeting, Hilton Head, SC, June 1998.

133.   Piazza NJ, Vrbka JL, Yeager RD.  Telescoping of alcoholism in women alcoholics. The International Journal of the Addictions  1989;24:19-28.

134.   Pickens R, Svikis D, McGue M, Lykken D, Heston L, Clayton P.  Heterogeneity in the inheritance of alcoholism.  Arch Gen Psychiatry  1991;48:19-28.

135.   Powell B, Campbell J, Landon J, Liskow B, Thomas H, Nickel D, Dale T, Penick E, Samuelson S, Lacoursiere R.  A double-blind, placebo-controlled study of nortriptyline and bromocriptin in male alcoholics subtyped by comorbid psychiatric disorders.   Alcohol Clin Exp Res  1995;19:462-468.

136.   Rasmussen K, Stockton M, Czachura J.  The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons.  European Journal of Pharmacology  1991;205:113-116.

137.   Rassnick S, D'Amico E, Riley E, Pulvirenti L, Zieglgansberger W, Koob G.  GABA and nucleus accumbens glutamate neurotransmission modulate ethanol self-administration in rats.  Annals of the New York Academy of Science  1992a;654:502-505.

138.   Rassnick N, Pulvirenti L, Koob G.  Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology  1992b;109:92-98.

139.   Rassnick N, Pulvirenti L, Koob G. SDZ-205,152, a novel dopamine receptor agonist, reduces oral ethanol self-administration in rats.   Alcohol  1993;10(2):127-132.

140.   Reid L, Delconte J, Nichols M, Bilsky E, Hubbell C.  Test of the opioid deficiency hypothesis of alcoholism.  Alcohol  1991;8:247-257.

141.   Ritchie J.  The aliphatic alcohols.  In: Gilman A, Goodman L, Rall T, Murad F, eds. The Pharmacological Basis of Therapeutics. (7^th Edition)  New York: Macmillan, 1985;372-386.

142.   Robbins L, Helzer J, Weissman M, Orvaschel H, Gruenberg E, Burke J, Regier D. Lifetime prevalence of specific psychiatric disorders in three sites.  Arch Gen Psychiatry 1984;41:949-958.

143.   Rockman G, Amit Z, Brown Z, Bourque C, Ogren S.  An investigation of the mechanisms of action of 5-hydrox-trptamine in the suppression of ethanol intake. Neuropharmacology  1982;21:341-347.

144.   Rossetti Z, Hmaidan Y, Gessa G.  Marked inhibition of mesolimbic release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol  1992;221:227-234.

145.   Samson H, Hodge C, Erickson H, Niehus J, Gerhardt G, Kalivas P, Floyd E.  The effect of local application of ethanol in the nucleus accumbens on dopamine overflow and clearance.  Alcohol  1997;14:485-492.

146.   Schwarz-Stevens K, Files F, Sansom H.  Effects of morphine and naloxone on ethanol- and sucrose-reinforced responding in nondeprived rats.  Alcoholism: Clinical and Experimental Research  1992;16:822-832.

147.   Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB.  Clinical Efficacy of the 5-HT3 Antagonist ondansetron in alcohol abuse and dependence. Alcoholism: Clinical and Experimental Research  1994;18:879-885.

148.   Shaw G, Majumdar S, Waller S, MacGarvie J, Dunn G.  Tiapride in the long-term management of alcoholics of anxious or depressive temperament.  Br J Psychiatry 1987;150:164-168.

149.   Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G.  Tiapride in prevention of relapse in recently detoxified alcoholics.  British Journal of Psychiatry 1994;165:515-523.

150.   Sigvardsson S, Bohman M, Cloninger C.  Replication of the Stockholm adoption study of alcoholism:  Confirmatory cross-fostering analysis.  Arch Gen Psych 1996;53:681-687.

151.   Sisson R, Azrin N.  Family-member involvement to initiate and promote treatment of problem drinkers.  J Behav Ther Exp Psychiatry  1986;17:15-21.

152.   Slawecki C, Hodge C, Samson H.  Dopaminergic and opioidergic agonists and antagonists differentially decrease multiple schedule responding maintained by sucrose/ethanol and sucrose.  Alcohol  1997;14:281-294.

153.   Spanagel R. The influence of opioid antagonists on the discriminative stimulus of ethanol.  Pharmacology, Biochemistry and Behavior  1996a;54:645-649.

154.   Spanagel R, Holter S, Allingham K, Landgraf R, Zieglgansberger W.  Acamprosate and alcohol I: effects on alcohol intake following alcohol deprivation in the rat.  European Journal of Pharmacology  1996b;305:505-509.

155.   Strohmetz D, Alterman A, Walter D.  Selection factors in alcoholics volunteering for a treatment study.  Alcoholism: Clin & Exp Res  1990;14:736-738.

156.   Stromberg M, Meister S, Volpicelli J, Ulm R.  Morphine enhances selection of both sucrose and ethanol in a two-bottle test.  Alcohol  1997;14:55-62.

157.   Stromberg M, Casale M, Volpicelli L, Volpicelli J, O'Brien C.  A comparison of the effects of the opioid antagonists naltrexone, naltrindole and b-funaltrexamine on ethanol consumption in the rat.  Alcohol  1998a;15:281-289.

158.   Stromberg M, Volpicelli J, O'Brien C.  The effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat.  Alcoholism: Clinical and Experimental Research 1998b;22:2186-2191.

159.   Sullivan J, Naranjo C, Sellers E.  Compliance among heavy alcohol users in clinical drug trials.  J Sub Abuse  1989;1:184-194.

160.   Suzdak P, Glowa J, Crawley J, Schwartz R, Skolnick P, Paul S.  A selective imidazobenzodiazepine antagonist of ethanol in the rat.  Science 1986a;234:1243-1247.

161.   Suzdak P, Schwartz R, Skolnick P, Paul S.  Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes.  Proc Natl Acad Sci  1986b;83:4071-4075.

162.   Svensson L, Engel J, Hard E.  Effects of the 5-HT receptor agonist 8-OH-DPAT, on ethanol preference in the rat.  Alcohol  1989;6:17-21.

163.   Swift R, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H.  Naltrexone-induced alterations in human ethanol intoxication.  Am J Psychiatry  1994;151:1463-1467.

164.   Tarter R, McBridge H, Buonpane N, Schneider D. Differentiation of alcoholics according to childhood history of minimal brain dysfunction, family history and drinking pattern.  Arch Gen Psychiatry  1977;34:761-768.

165.   Tollefson G, Montagu-Clouse J, Lancaster S.  Buspirone in comorbid alcohol dependency and generalized anxiety disorders.  Ther Bull  1990;August:35-50.

166.   Turnbull JD, Gomberg ES.  Impact of depressive symptomatology on alcohol problems in women.  Alcoholism: Clinical and Experimental Research  1988;12:374-381.

167.   Varmus H.  NIH Guidelines on the inclusion of women and minorities as subjects in clinical research; notice.  Federal Register 1994;59:14508-14513.

168.   Vavrousek-Jakuba E, Cohen C, Shoemaker W.  Ethanol effects of CNS dopamine receptors: in vivo binding following voluntary ethanol (ETOH) intake in rats.  In:  Naranjo C, Sellers E, eds.  Novel Pharmacological Inverventions for Alcoholism. New York: Springer-Verlag, 1992;372-374.

169.   Vescovi P, Coiro V, Volpi R, Giannini A, Passeri M.  Plasma beta-endorphin but no metenkephalin levels are abnormal in chronic alcoholics.  Alcohol & Alcoholism  1992;27(5):471-475.

170.   Volpicelli J, Davis M, Olin J.  Naltrexone blocks the post-shock increase of ethanol consumption.   Life Sci 1986;38:841-847.

171.   Volpicelli J, Alterman A, Hayashida M, O'Brien C.  Naltrexone in the treatment of alcohol dependence.   Arch Gen Psychiatry  1992;49:876-880.

172.   Volpicelli J, Watson N, King A, Sherman C, O'Brien C.  Effect of naltrexone on alcohol "high" in alcoholics.  Am J Psychiatry  1995;152:613-615.

173.   von Knorring L, von Knorring A, Smigan L, Lindberg U, Edholm P.  Personality traits in subtypes of alcoholics.  J Stud Alcohol  1987;48:523-527.

174.   Walaas I.  Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience  1981;6:399-405.

175.   Weiss F, Mitchner F, Bloom F, Koob G.  Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology 1990;101:178-186.

176.   Weiss F, Lorang M, Bloom F, Koob G.  Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens; genetic and motivational determinants.  J Pharmacol and Experi Therapeu  1993;267:250-258.

177.   Wilde MI, Wagstaff AJ.  Acamprosate: A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.  Drugs 1997;53:1038-1053.

178.   Wilkinson P.  Sex differences in morbidity of alcoholics.  In: Kalant  O, ed. Alcohol and Drug Problems in Women:  Research Advances in Alcohol and Drug Problems. New York: Plenum Press, 1980;331-364.

179.   Williams K, Woods J.  Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for m, k, d-receptor.  Alcoholism: Clinical and Experimental Research  1998;22:1634-1639.

180.   Wilsnack SC, Wilsnack RW.  Drinking and problem drinking in US women: patterns and recent trends.  In:  Galanter M, ed. Recent Developments in Alcoholism..  New York: Plenam Press, 1995;29-60.

181.   Wozniak K, Pert A, Linnoila M.  Antagonism of 5HT3 receptors attenuates the effects of ethanol on extracellular dopamine.  Eur J Pharamcol  1990;187:287-289.

182.   Wozniak K, Pert A, Mele A, Linnoila M.  Focal application of alcohol elevates extracellular dopamine in rat brain: a microdialysis study.  Brain Res  1991;549:31-40.

183.   Yim H, Schallert T, Randall P, Gonzales R.  Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis.   Alcoholism: Clinical and Experimental Research  1998;22:367-374.

184.   Yoshimoto K, McBride W, Lumeng L, Li T-K.  Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens.  Alcohol  1991;9:17-22.

185.   Yoshimoto K, McBride W, Lumeng L, Li T-K.  Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAA lines of rats. Alcohol Clin Exp Res  1992;16:781-785.

186.   Zeise M, Kasparov S, Capogna M, Zieglgansberger W.  Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors.  European Journal of Pharmacology 1993;231:47-52.

187.   Zhou F, Zhang J, Lumeng L, Li T-K.  Mesolimbic dopamine system in alcohol preferring rats.   Alcohol  1995;12:403-412.

188.   Zhou F, McKinzie D, Patel T, Lumeng L, Li T-K.  Additive reduction of alcohol drinking by 5-HT1a antagonist WAY100635 and serotonin uptake blocker fluoxetine in alcohol-preferring rats.  Alcoholism: Clinical and Experimental Research 1998;22:266-269.

Back to Chapter

published 2000